Posted by Michael Wonder on 03 Mar 2022
FDA approves Kaléo’s naloxone auto-injector 10 mg for the treatment of known or potential exposure to ultra-potent weaponised opioids
2 March 2022 - Product received fast-track designation for military personnel facing the potential threat of exposure to synthetic opioids on the battlefield on behalf of the U.S. Department of Defense.
Kaléo today announced that the U.S. FDA has approved its naloxone auto-injector 10 mg indicated for the emergency treatment of people 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon, is suspected.
